Dimethyl Sulfoxide
Apexbio Technology LLC Tigecycline 220620-09-7 10mM (in 1mL DMSO)
Tigecycline is a glycylcycline-class antibiotic developed as a structural derivative of tetracycline antibiotics It exerts antimicrobial activity by reversibly binding to the bacterial 30S ribosomal subunit leading to inhibition of protein synthesis Tigecycline demonstrates bacterial growth inhibition in both Gram-positive and Gram-negative pathogens including multidrug-resistant strains In vitro studies showed minimal inhibitory concentration (MIC90) values ranging between 0 12-0 5 g/ml against vancomycin-sensitive and resistant Enterococcus faecalis and Enterococcus faecium In animal infection models using MRSA strains Tigecycline displays in vivo efficacy with an ED50 approximately 0 72 mg/kg This antibiotic is commonly employed in research studies focusing on resistant bacterial infections such as complicated skin infections and intra-abdominal infections
Apexbio Technology LLC Bedaquiline 843663-66-1 10mM (in 1mL DMSO)
Bedaquiline a diarylquinoline antibiotic targets Mycobacterium tuberculosis via dual inhibition of subunits c and within the bacterial F1FO-ATP synthase complex disrupting ATP production It is applied primarily in research addressing multi-drug resistant (MDR) tuberculosis Recent studies have expanded its use into oncology where bedaquiline inhibits mitochondrial respiratory function and reduces glycolytic activity in cancer stem-cell-like populations In vitro experiments employing breast cancer MCF7 cells revealed bedaquiline increased ROS levels and reduced mitochondrial membrane potential Reported IC50 values for growth inhibition range approximately 1-10 M depending on cell lines and experimental conditions
Medchemexpress LLC Ly2090314 1Ml Dmso Reconstitut | HY-16294-1ML DMSO RECONST
Ly2090314 1Ml Dmso Reconstitut
Apexbio Technology LLC AT9283 896466-04-9 10mM (in 1mL DMSO)
AT9283 (CAS 896466-04-9) is a synthetic small-molecule inhibitor developed through fragment-based drug design It inhibits Aurora kinases A and B key components of the serine/threonine kinase family involved in regulating cell division processes as well as targets including Janus kinases (JAKs) BCR-ABL kinase (including the T315I mutant) and Flt-3 With a potent IC50 around 3 nM against Aurora kinases AT9283 exhibits antiproliferative and pro-apoptotic activity in leukemia myeloproliferative diseases solid tumors and B-cell lymphoma models It is utilized primarily in cancer biology research to investigate its therapeutic potential targeting aberrant kinase activity
Apexbio Technology LLC LY2228820 862507-23-1 10mM (in 1mL DMSO)
LY2228820 (CAS 862507-23-1) is a potent selective ATP-competitive small-molecule inhibitor targeting the and isoforms of p38 mitogen-activated protein kinase (MAPK) with reported IC50 values of 5 3 nM and 3 2 nM respectively By suppressing p38 MAPK signaling LY2228820 decreases phosphorylation of heat shock protein 27 (HSP27) induced by Bortezomib thereby elevating cytotoxic effects in multiple myeloma (MM) models Additionally it inhibits secretion of IL-6 by bone marrow mononuclear cells and stromal cells as well as secretion of MIP-1 by patient-derived MM cell subsets and osteoclast precursors In melanoma (B16-F10) and NSCLC (A549) xenograft murine models LY2228820 reduces phosphorylation of MK2 and slows tumor progression respectively highlighting its potential utility in oncology research
Apexbio Technology LLC D4476 301836-43-1 10mM (in 1mL DMSO)
D4476 (CAS 301836-43-1) is a selective cell-permeable inhibitor of casein kinase 1 (CK1) and ALK5 exhibiting IC50 values of 0 3 M for CK1 and 0 5 M for ALK5 (at 0 1 mM ATP in vitro) It likely acts via ATP-competitive inhibition of CK1 showing minimal to no significant inhibitory activity against SAPK2a/p38 PKB or SGK Treatment with D4476 inhibits CK1-mediated phosphorylation of FOXO1a (Ser322 and Ser325) and RhoB (Ser185) in H4IIE and HeLa cells respectively impacting downstream processes such as nuclear export dynamics and actin cytoskeleton regulation Additionally it induces partial p53-dependent growth arrest in HCT116 cells
Apexbio Technology LLC Gliclazide 21187-98-4 10mM (in 1mL DMSO)
Gliclazide (CAS 21187-98-4) is an oral hypoglycemic agent classified structurally as a sulfonylurea derivative It exerts its biological effects primarily by targeting pancreatic beta-cell sulfonylurea receptors (SUR1) stimulating insulin secretion through the closure of ATP-dependent potassium channels This channel inhibition induces cellular depolarization facilitating calcium influx and subsequent insulin exocytosis In a research context gliclazide is utilized extensively as a pharmacological tool to study pancreatic beta-cell function insulin secretion dynamics and diabetic pathophysiology
Selleck Chemical LLC GSK2256098 10mM 1mL in DMSOPurity 99.82
GSK2256098 10mM 1mL in DMSOPurity 99.82
Apexbio Technology LLC (S)-(+)-Ibuprofen(Synonyms: Dexibuprofen, (S)-Ibuprofen, (S)-(+)-2-(4-Isobutylphenyl)propionic acid), 10mM (in 1mL DMSO), CAS: 51146-56-6.
(S)-( )-Ibuprofen (CAS 51146-56-6) is the pharmacologically active enantiomer of the racemic nonsteroidal anti-inflammatory drug (NSAID) ibuprofen Unlike its R(-)-counterpart the S( )-form selectively inhibits cyclooxygenase (COX) enzymes thereby suppressing prostaglandin synthesis at concentrations relevant to clinical settings Due to this stereoselectivity (S)-( )-ibuprofen is widely utilized in biomedical research investigating pain inflammation pathways COX enzyme activity and related drug-target interactions
Apexbio Technology LLC RG7388 1229705-06-9 10mM (in 1mL DMSO)
RG7388 (CAS 1229705-06-9) is a second-generation selective inhibitor of the MDM2-p53 interaction It functions by blocking the binding between MDM2 and wild-type p53 thereby stabilizing and activating the p53 tumor-suppressor pathway In human cancer cell lines RG7388 shows high potency with reported IC50 values of 6 nM (MDM2 binding assay) and 0 03 M (MTT assay) Preclinical studies demonstrate cell-cycle arrest and apoptosis selectively in wild-type p53-expressing cells and tumor regression in xenograft mouse models including sarcoma and neuroblastoma RG7388 is currently under clinical evaluation for multiple solid and hematologic malignancies
Apexbio Technology LLC Tinidazole 19387-91-8 10mM (in 1mL DMSO)
Tinidazole is a synthetic nitroimidazole derivative with antiparasitic and antibacterial activity used to study protozoal infections and anaerobic bacterial conditions After cellular uptake it is activated by nitroreductase enzymes forming cytotoxic metabolites that induce DNA strand breaks and inhibit nucleic acid synthesis leading to cell death Tinidazole is commonly used in vitro to evaluate its efficacy against pathogens like Giardia lamblia Trichomonas vaginalis and Entamoeba histolytica IC50 values against Giardia lamblia trophozoites typically range from 0 5 to 5 M making it a useful tool for antiparasitic drug screening and antimicrobial studies
Apexbio Technology LLC NVP-AEW541 475489-16-8 10mM (in 1mL DMSO)
NVP-AEW541 (CAS 475489-16-8) is a selective small-molecule inhibitor targeting the insulin-like growth factor-I receptor (IGF-IR) kinase activity Structurally classified as a pyrrolo[2 3-d]pyrimidine derivative NVP-AEW541 effectively inhibits IGF-IR autophosphorylation disrupting downstream IGF-IR mediated signaling cascades It exhibits an IC50 of approximately 0 086 M against IGF-IR kinase In vitro research has demonstrated that treatment of ECC-1 and USPC-1 endometrial cancer cell lines with NVP-AEW541 leads to altered cell cycle progression induction of apoptosis and suppression of proliferation Furthermore NVP-AEW541 has been shown to enhance radiosensitivity specifically in PTEN wild-type cancer cell lines indicating its potential utility as an adjunctive therapeutic agent in oncology research